Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 14;41(11):271.
doi: 10.1007/s12032-024-02497-0.

The role of kinesin superfamily proteins in hepatocellular carcinoma

Affiliations
Review

The role of kinesin superfamily proteins in hepatocellular carcinoma

Zahraa Sabah Ghnim et al. Med Oncol. .

Abstract

The most prevalent form of primary liver cancer, hepatocellular carcinoma (HCC) poses a significant global health challenge due to its limited therapeutic options. Researchers are currently focused on the complex molecular landscape that governs the initiation and progression of HCC in order to identify new avenues for diagnosis, prognosis, and treatment. In the context of HCC, the Kinesin Superfamily Proteins (KIFs) have become critical regulators of cellular processes, prompting a growing interest in their function among the diverse array of molecular actors implicated in cancer. The KIFs, a family of microtubule-based molecular motors, are renowned for their essential roles in the dynamics of mitotic spindles and intracellular transport. Beyond their well-established functions in normal cellular physiology, emerging evidence indicates that dysregulation of KIFs significantly contributes to the pathogenesis of HCC. Novel therapeutic targets and diagnostic markers are revealed through the unique opportunity to comprehend the complex interplay between KIFs and the molecular events that drive HCC.

Keywords: Hepatocellular carcinoma; Kinesin superfamily; Kinesin superfamily proteins; Metastasis.

PubMed Disclaimer

References

    1. El-Serag HB, Lau M, Eschbach K, Davila J, Goodwin J. Epidemiology of hepatocellular carcinoma in Hispanics in the United States. Arch Intern Med. 2007;167(18):1983–9. - PubMed
    1. Yopp AC, Singal AG. Epithelial to mesenchymal transition expression profiles as predictive biomarkers of recurrence following resection of HCC: implications for current clinical use and future stratification for systemic therapy. Ann Surg Oncol. 2014;21:3723–4. - PubMed
    1. Maluccio M, Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin. 2012;62(6):394–9. - PubMed
    1. Hu X, Zhu H, Shen Y, Zhang X, He X, Xu X. The role of non-coding RNAs in the sorafenib resistance of hepatocellular carcinoma. Front Oncol. 2021;11: 696705. - PubMed - PMC
    1. Huang A, Zhao X, Yang X-R, Li F-Q, Zhou X-L, Wu K, et al. Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma. J Hepatol. 2017;67(2):293–301. - PubMed

MeSH terms

LinkOut - more resources